Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.2147/DMSO.S130834</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630703">http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630703</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

Philip A Levin1
Hiep Nguyen2
Eric T Wittbrodt2
Seoyoung C Kim3

1Bay West Endocrinology Associates, Baltimore, MD, 2Health Economics and Outcomes Research, AstraZeneca, Wilmington, DE, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety.

Objective: Published evidence directly comparing GLP-1RAs with other approved treatments for type 2 diabetes (T2D) was systematically reviewed.

Methods: A literature search was performed using MEDLINE and Embase databases to identify papers comparing GLP-1RAs with other classes of glucose-lowering therapy in patients with T2D.

Results: Of the 1303 papers identified, 57 met the prespecified criteria for a high-quality clinical trial or retrospective study. The efficacy and tolerability of approved GLP-1RAs (exenatide twice daily or once weekly, dulaglutide, liraglutide, lixisenatide, and albiglutide) were compared with insulin products (23 prospective studies + seven retrospective studies), dipeptidyl peptidase-4 inhibitors (11 prospective studies + three retrospective studies), sulfonylureas (nine prospective studies + one retrospective study), thiazolidinediones (five prospective studies), and metformin (two prospective studies). GLP-1RAs are effective as a second-line therapy in improving glycemic parameters in patients with T2D. Reductions in glycated hemoglobin from baseline with GLP-1RAs tended to be greater or similar compared with insulin therapy. GLP-1RAs were consistently more effective in reducing body weight than most oral glucose-lowering drugs and insulin and were associated with lower hypoglycemia risk versus insulin or sulfonylureas. GLP-1RAs improved cardiovascular risk factors, and preliminary data suggest they improve cardiovascular outcomes in patients with T2D compared with oral glucose-lowering drugs. However, results from ongoing studies are awaited to confirm these early findings.

Conclusion: This systematic review found that GLP-1RAs are an effective class of glucose-lowering drugs for T2D.

Keywords: antidiabetic drugs, randomized controlled trials, retrospective, type 2 diabetes

Introduction
Diabetes mellitus is a chronic disease affecting a substantial proportion of the population.1 In adults (age 20–79 years), the 2015 prevalence of diabetes worldwide was estimated at 8.8%, with type 2 diabetes (T2D) comprising 91% of cases.2 By 2030, diabetes is expected to be the seventh leading cause of death.3

Several classes of glucose-lowering agents are currently available for the treatment of T2D, each with different mechanisms of action and therapeutic effects. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of glucose-lowering drugs that act on the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells and increase insulin secretion, decrease glucagon secretion, slow gastric emptying, and increase satiety; clinical trials have shown that GLP-1RAs decrease body weight,
postprandial glucose excursions, and some cardiovascular risk factors, without increasing the risk of hypoglycemia. Clinical trials have also studied the effects of GLP-1RA therapy on cardiovascular outcomes in patients with T2D. The purpose of this systematic review was to compare the efficacy of GLP-1RAs with other glucose-lowering therapies, using comparative data from clinical trials or observational cohort studies.

**Literature search strategy and filtering**

Embase and MEDLINE databases were searched on April 8, 2016, using the following search string: (glucagon like peptide 1 receptor agonist or “Glucagon-Like Peptide 1”) OR (“Glucagon-like peptide 1” or GLP1R or GLP-1 or GLP-1-R) AND (agonist or suppress* or block* or inhibit* or anti* or mimetic) OR (lixisenatide or exenatide or liraglutide or albiglutide or dulaglutide) AND ([diabetes or diabetic or DM] and [“Type 2” or “Type-2” or “Type 2” or “Type II” or “Noninsulin-dependent” or “Non insulin-dependent” or “Non insulin dependent”]).

The search string was limited to keywords in the abstract or title. Articles indexed as animal studies, case reports, books, and conference/symposium presentations were excluded. The limits applied were English language and articles published between January 2005 and April 2016. Duplicates were removed, leaving 1303 articles. The articles identified were filtered manually and only those describing a head-to-head comparison between a GLP-1RA and another class of glucose-lowering therapy in ≥100 patients, regardless of study design, follow-up duration, or medication doses, were included in the final total.

A total of 57 articles were included in the analysis (Figure 1); of these, 37 were randomized controlled trials (RCTs), seven were open-label extensions of RCTs, 11 were retrospective analyses, and two were prospective observational studies.

**Efficacy of GLP-1RAs versus other glucose-lowering therapies**

GLP-1RAs versus dipeptidyl peptidase-4 inhibitors (DPP-4is)

Eleven prospective studies7–17 and three retrospective studies compared GLP-1RAs with DPP-4is.18–20

**Prospective studies**

Exenatide once weekly (QW) was associated with significantly greater (P < 0.001) reductions in glycated hemoglobin (HbA1c) and fasting glucose (FG) compared with sitagliptin after 26 weeks in the Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly (DURATION)-2 and DURATION-4 studies (Table 1).8,9 Although both exenatide QW and sitagliptin recipients lost weight, patients receiving exenatide QW had significantly greater weight loss from baseline.8,9 One study comparing exenatide twice daily (BID) with sitagliptin found that exenatide BID recipients had a reduction in FG similar to sitagliptin recipients, but a significantly greater reduction in weight.7

In the Assessment of Weekly Administration of LY2189265 in Diabetes (AWARD)-5 study, after 52 weeks of treatment, reductions from baseline in HbA1c, FG, and weight were significantly greater with dulaglutide than with sitagliptin (Table 1).10 These benefits were sustained over 104 weeks of treatment.11

Generally, lixisenatide-treated patients had greater or similar reductions from baseline in HbA1c, FG, and weight compared with sitagliptin- or vildagliptin-treated patients (Table 1).12–14,16 In an open-label extension study, patients switching from sitagliptin to lixisenatide had further reductions in these parameters.15

When administered for 24 weeks, lixisenatide produced reductions from baseline in HbA1c and FG that were similar to sitagliptin (Table 1);17 however, weight loss was significantly greater among lixisenatide versus sitagliptin recipients.

Hypoglycemia rates in patients receiving GLP-1RAs or DPP-4is were low, with only one instance of major/severe hypoglycemia reported across all studies (in a patient receiving lixisenatide 1.2 mg).13,14 In studies of exenatide QW, minor hypoglycemia rates ranged from 1% to 3.6% with exenatide QW, with the highest hypoglycemia rates for concomitant sulfonylurea use, and from 0% to 3.0% with DPP-4is.7–9 Patients receiving dulaglutide 1.5 mg generally had numerically higher hypoglycemia rates than patients receiving dulaglutide 0.75 mg or sitagliptin (10.2% vs 5.3% and 4.8%; 12.8% vs 8.6% and 8.6%, respectively).10,12 Rates of hypoglycemia were similar for all lixisenatide doses investigated versus DPP-4i comparators.12–14,16 Furthermore, the incidence of gastrointestinal adverse events (AEs; nausea, diarrhea, and vomiting) was higher7–11,13–15,17 or similar16 in patients receiving GLP-1RAs versus DPP-4is; gastrointestinal AEs led to treatment withdrawal in a higher percentage of patients receiving GLP-1RA therapy in these studies.5,10,11 Some studies reported that gastrointestinal AEs peaked on treatment initiation in the GLP-1RA group and then stabilized over the study period.10,11,13
Records identified through MEDLINE and Embase searches (N = 1303)

Records excluded:
- Non-English language (n = 6)
- Reviews (n = 260)
- Systematic review or meta-analysis (n = 45)
- Protocol (n = 17)
- Editorial/letter/commentary/news/erratum (n = 59)
- Case reports (n = 56)
- Preclinical (n = 119)
- Simulation/modeling (n = 6)

Clinical trials assessed for eligibility (n = 735)

Trials excluded:
- Inappropriate comparator (n = 130)
  - No comparator (n = 49)
  - GLP-1RA not specified (n = 23)
  - Comparator not specified (n = 3)
  - Not GLP-1RAs (n = 28)
  - Nonclinical endpoint (n = 53)
  - Not type 2 diabetes (n = 158)
- Pharmacodynamics/pharmacokinetics (n = 72)
- Pharmacoeconomic (n = 56)
- Duplicate (n = 24)
- Study n<100 (n = 44)
- Baseline characteristics only reported (n = 3)
- Subanalysis (n = 5)
- Pooled analysis (n = 29)
- Not a clinical study (n = 1)

Studies included (n = 57)

Retrospective studies

Retrospective studies had similar results to the prospective studies (Table 2), with GLP-1RAs demonstrating greater or similar reductions in HbA1c, FG, and weight versus DPP-4is. Generally, hypoglycemia rates were not reported, although in one study the rate was similar between GLP-1RAs and DPP-4is. Nausea/vomiting was more frequent with exenatide compared with sitagliptin (incidence rate, 0.39 vs 0.032) in one study.

GLP-1RAs versus metformin

Two prospective studies comparing GLP-1RAs and metformin were identified.

Prospective studies

Both studies (RCTs) reported reductions from baseline in HbA1c, FG, and weight (Table 1). In DURATION-4, exenatide QW and metformin reduced HbA1c from baseline by ~1.5%, with no significant difference between groups at 26 weeks. In AWARDD-3, dulaglutide 0.75 mg and 1.5 mg QW reduced HbA1c significantly more than metformin (P < 0.05) after 26 weeks. After 52 weeks, significant differences were observed in the reduction from baseline in HbA1c between dulaglutide 1.5 mg and metformin, but not between dulaglutide 0.75 mg and metformin.

Two RCTs investigated the effects of exenatide QW and dulaglutide on FG and weight, with no significant differences between these drugs in the reductions of these endpoints at 26 weeks. Treatment with dulaglutide at both dosages resulted in similar reductions in FG versus metformin at 26 weeks; at 52 weeks, recipients of dulaglutide 1.5 mg had a significantly greater reduction in FG than metformin recipients (P < 0.05; Table 1). The magnitude of weight loss achieved in
Dipeptidyl peptidase-4 inhibitors

<table>
<thead>
<tr>
<th>Publications (acronym/ ClinicalTrials.gov record)</th>
<th>Study design (study duration)</th>
<th>Treatment (patient number)</th>
<th>Background therapy</th>
<th>Change from baseline at study end, GLP-1RAs versus comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berg et al⁷</td>
<td>CO, DB, DD, R in pts with T2D (2 × 4 weeks)</td>
<td>ExBID 10 µg/SITA 100 mg QD (41)</td>
<td>MET (n = 82) TDZ (n = 1)</td>
<td>HbA1c (%)</td>
</tr>
<tr>
<td>Bergenstal et al⁷ (DURATION-2; NCT00637273)</td>
<td>DB, DD, MC, PG, R in pts with T2D (26 weeks)</td>
<td>ExQW 2 mg (160)</td>
<td>MET</td>
<td>ExQW: –1.5***</td>
</tr>
<tr>
<td>Russell-Jones et al⁷ (DURATION-4; NCT00766338)</td>
<td>DB, MC, PG, R in treatment-naive pts with T2D (26 weeks)</td>
<td>ExQW 2 mg (248)</td>
<td>None</td>
<td>ExQW: –1.5***</td>
</tr>
<tr>
<td>Nauck et al¹⁵ (AWARD-5; NCT00734474)</td>
<td>DB, MC, PG, R in pts with T2D (52 weeks)</td>
<td>DULA 0.75 mg QW (302)</td>
<td>MET</td>
<td>DULA 0.75: –0.9***</td>
</tr>
<tr>
<td>Weinstock et al¹¹ (AWARD-5; NCT00734474)</td>
<td>DB, MC, PG, R in pts with T2D (104 weeks)</td>
<td>DULA 0.75 mg QW (304)</td>
<td>MET</td>
<td>DULA 1.5: –1.1***</td>
</tr>
<tr>
<td>Charbonnel et al¹² (NCT01296412)</td>
<td>OL, MC, PG, R in pts with T2D (26 weeks)</td>
<td>LIRA 1.2 mg/day* (253)</td>
<td>MET</td>
<td>LIRA: –1.4</td>
</tr>
<tr>
<td>Pratley et al¹³ (NCT00700817)</td>
<td>OL, MC, PG, R in pts with T2D (52 weeks)</td>
<td>LIRA 1.2 mg/day (225)</td>
<td>MET</td>
<td>LIRA: –1.3</td>
</tr>
<tr>
<td>Pratley et al¹³ (NCT00700817)</td>
<td>OL extension of pts with T2D completing the 1860-LiRA-DPP-4 core study (26 weeks)</td>
<td>LIRA 1.0 mg (219)</td>
<td>MET</td>
<td>LIRA: –1.0***</td>
</tr>
<tr>
<td>Takeshita et al¹⁴</td>
<td>OL, PG, R in Japanese pts with T2D not adequately controlled by SITA-based therapy (12 weeks)</td>
<td>LIRA 0.9 mg QD (54)</td>
<td>None</td>
<td>LIRA: –0.7*</td>
</tr>
<tr>
<td>Van Gaal et al¹⁷ (NCT00976937)</td>
<td>DB, DD, MC, PG, R in young, obese pts with T2D (24 weeks)</td>
<td>LiXi 20 µg QD (158)</td>
<td>MET</td>
<td>LiXi: –0.7</td>
</tr>
<tr>
<td>Metformin</td>
<td>DB, MC, PG, R in treatment-naive pts with T2D (26 weeks)</td>
<td>ExQW 2 mg (248)</td>
<td>None</td>
<td>ExQW: –1.5</td>
</tr>
<tr>
<td>Umpierrez et al¹⁰ (AWARD-3; NCT00766338)</td>
<td>DB, DD, MC, PG, R in pts with T2D (52 weeks)</td>
<td>DULA 0.75 mg QW (270)</td>
<td>MET</td>
<td>DULA 0.75: –0.7#</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DULA 1.5 mg QW (269)</td>
<td>MET</td>
<td>DULA 1.5: –0.8**</td>
</tr>
</tbody>
</table>

(Continued)
### Table 1 (Continued)

<table>
<thead>
<tr>
<th>Publications (acronym/ ClinicalTrials.gov record)</th>
<th>Study design (study duration)</th>
<th>Treatment (patient number)</th>
<th>Background therapy</th>
<th>Change from baseline at study end, GLP-1RAs versus comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>HbA1c (%)</td>
<td>FG (mmol/L)</td>
</tr>
</tbody>
</table>

**Sulfonylureas**

Derosa et al\(^2\)  
MC, R, SB in overweight pts with T2D poorly controlled on Met (12 months)  
GLYB 5 mg TID\(^3\) (65)  
MET  
ExBiD: −1.5  
GLYB: −1.8  
GLYB: −1.8  
GLYB: +4.3

Derosa et al\(^2\)  
MC, R, SB in overweight pts with T2D poorly controlled on Met (12 months)  
GLIM 2 mg TID\(^3\) (54)  
MET  
ExBiD: −1.2  
GLIM: −1.4  
GLIM: −1.6  
GLIM: −0.9

Galwitz et al\(^3\)  
OL, R, MC in overweight pts with T2D poorly controlled on Met (~3 years)  
GLIM 1 mg TID\(^3\) (487)  
MET  
ExBiD: −0.4\(^**\)  
GLIM: −0.2  
GLIM: −0.4  
GLIM: +1.2

Nauck et al\(^2\)  
(LEAD-2; NCT00318461)  
DB, DD, MC, PG, R in pts with T2D (26 weeks)  
LIRA 0.6 mg QD (242)  
MET  
LIRA 0.6: −0.7  
LIRA 1.2: −1.0  
LIRA 1.8: −1.0  
GLIM 4: −1.0  
GLIM 4: −1.3  
GLIM 4: +1.0

Nauck et al\(^2\)  
(LEAD-2; NCT00318461)  
OL extension of pts with T2D completing the LEAD-2 core study (18 months)  
GLIM 4 mg QD (183)  
MET  
LIRA 0.6: −0.4  
LIRA 0.6: −0.8  
LIRA 1.2: −1.6  
LIRA 1.8: −1.7  
GLIM 4: −0.5  
GLIM 4: −0.6  
GLIM 4: +0.7

Garber et al\(^5\)  
(LEAD-3 Mono; NCT00294723)  
DB, DD, MC, PG, R in pts with early T2D (52 weeks)  
GLIM 8 mg QD (484)  
MET  
LIRA 1.2: −0.8\(^***\)  
LIRA 1.8: −1.1\(^**\)  
GLIM: −0.5  
GLIM: −0.3  
GLIM: +1.1

Garber et al\(^6\)  
(LEAD-3 Mono; NCT00294723)  
OL extension of pts with T2D completing the LEAD-3 core study (52 weeks)  
GLIM 8 mg QD (97)  
MET  
LIRA 1.2: −0.9\(^*\)  
LIRA 1.8: −1.1\(^**\)  
GLIM: −0.6  
GLIM: −0.3  
GLIM: +1.1

Seino et al\(^7\)  
(NCT00393718)  
DB, DD, MC, PG, R in Japanese pts with T2D (24 weeks)  
GLYB 2.5 mg/day\(^d\) (139)  
None  
LIRA: −1.9\(^***\)  
GLYB: −1.4  
GLYB: −2.9  
GLYB: +1.0

Kaku et al\(^7\)  
(NCT00393718)  
OL extension of Seino study in Japanese pts with T2D (52 weeks)  
GLYB 2.5 mg/day\(^d\) (132)  
None  
LIRA: −1.5  
GLYB: −1.0  
GLYB: −2.5  
GLYB: +1.0

**Thiazolidinediones**

DeFronzo et al\(^8\)  
(NCT00135330)  
OL, MC, PG, R in MET-treated pts with T2D (20 weeks)  
ExBiD 10 µg\(^d\) (45)  
MET  
ExBiD: −0.9  
ROSI: −1.0  
ROSI: −1.8  
ROSI: +1.5

Xu et al\(^9\)  
(CONFIDENCE; NCT01147627)  
OL, MC, PG, R in treatment-naive pts with newly diagnosed T2D (48 weeks)  
ExBiD 10 µg\(^d\) (142)  
None  
ExBiD: −1.9\(^**\)  
ExBiD: −2.3\(^***\)  
PIO: −0.2  
PIO: 0

Bergenstal et al\(^8\)  
(DURATION-2; NCT00637273)  
DB, DD, MC, PG, R in pts with T2D (26 weeks)  
ExQw 2 mg (160)  
None  
ExQw: +1.5  
ExQw: +2.8

(Continued)
AWARD-3 was similar between the dulaglutide 1.5 mg and metformin groups at 26 and 52 weeks; dulaglutide 0.75 mg recipients lost significantly less weight than patients receiving metformin at both time points.

Minor hypoglycemia was reported in 2.0% of exenatide QW recipients versus 0.0% of metformin recipients, while dulaglutide and metformin recipients had similar total hypoglycemia rates (12.3%, 11.1%, and 12.7% for dulaglutide 1.5 mg, dulaglutide 0.75 mg, and metformin, respectively).

The incidence of gastrointestinal AEs was similar between treatment groups in AWARD-3, whereas in DURATION-4, nausea was reported in 11.3% and vomiting in 4.8% of exenatide-treated patients compared with 3.3% who experienced vomiting on metformin.

GLP-1RAs versus sulfonylureas

Nine prospective studies investigated the comparative efficacy of GLP-1RAs and sulfonylureas. One retrospective study was identified: a comparison of lixisenatide and glimepiride in outpatients in Italy.

Prospective studies

Generally, exenatide BID recipients had greater or similar reductions from baseline in HbA1c, FG, and weight compared with glyburide or glimepiride recipients (Table 1). The incidence of gastrointestinal AEs was generally higher with GLP-1RAs compared with sulfonylureas; however, one study reported similar incidence of gastrointestinal AEs with exenatide and glibenclamide. The incidence of treatment withdrawal due to gastrointestinal AEs was also higher with GLP-1RAs compared with sulfonylureas; differences in rates of gastrointestinal AEs were seen within 4 weeks in three studies and within 6 months in another study.

Retrospective studies

In the retrospective analysis, lixivatide produced significantly greater reductions in HbA1c and FG from baseline compared with glimepiride (Table 2; $P < 0.001$).

**Table 1 (Continued)**

<table>
<thead>
<tr>
<th>Publications (acronym/ ClinicalTrials.gov record)</th>
<th>Study design (study duration)</th>
<th>Treatment (patient number)</th>
<th>Background therapy</th>
<th>Change from baseline at study end, GLP-1RAs versus comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Russell-Jones et al (DURATION-4; NCT00676338)</td>
<td>DB, MC, PG, R in treatment-naive pts with T2D (26 weeks)</td>
<td>ExQW 2 mg (248)</td>
<td>None</td>
<td>HbA1c (%)</td>
</tr>
<tr>
<td>Marre et al (LEAD-1 SU; NCT00318422)</td>
<td>DB, DD, MC, PG, R in pts with T2D treated with oral GLT for ≥ 3 months (26 weeks)</td>
<td>LIRA 0.6 mg (233)</td>
<td>GLIM</td>
<td>None</td>
</tr>
</tbody>
</table>

**Notes:** *After 12 weeks, LIRA up-titrated to 1.8 mg/day in patients with HbA1c ≥ 7.0% (53 mmol/mol); † after 12 weeks, GLIM 1 or 2 mg/day added to regimen of patients with HbA1c ≥ 7.0% (53 mmol/mol) and FG > 6.1 mmol/L; ‡ primary end point was the change from baseline in HbA1c at 26 weeks. Secondary end points included the change from baseline in HbA1c at 52 weeks, and the change from baseline in FG and BW at 26 and 52 weeks; & dosage adjusted every 4 weeks up to the maximum tolerated dosage according to country-specific labeling information; †† dosage was titrated according to self-monitored blood glucose levels; *P < 0.05; **P < 0.01; ***P < 0.001; GLP-1RA versus comparator; †P < 0.001; ††P < 0.0001 versus baseline (start of extension); ‡† P < 0.05 versus LIRA 1.2 mg.

**Abbreviations:** AWARD, Assessment of Weekly Glycaemic Control and β-Cell Function Amongst Newly Diagnosed Patients With Type 2 Diabetes Treated With Exenatide, Insulin or Pioglitazone: A multicentre Randomised Parallel-Group Study; DB, double blind; DD, double dummy; DPP-4, dipeptidyl peptidase 4; DUAL, dulaglutide; DURATION, Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through intervention with exenatide Once weekly; EUREXA, European Exenatide Study; ExBiD, exenatide twice daily; ExQW, exenatide once weekly; FG, fasting glucose; GLIM, glimepiride; GLP-1RA, glucagon-like peptide-1 receptor agonist; GLT, glucose-lowering therapy; GLYB, glyburide; HbA1c, glycated hemoglobin; iLis, insulin lispro; LeAD, Liraglutide effect and Action in Diabetes; LiRA, liraglutide; LiXi, lixisenatide; MC, multicenter; MeT, metformin; NR, not reported; OL, open label; PBO, placebo; PG, parallel group; Pio, pioglitazone; pts, patients; QD, once daily; QW, once weekly; R, randomized; ROSI, rosiglitazone; SB, single blind; SITA, sitagliptin; T2D, type 2 diabetes; TID, three times a day; TZD, thiazolidinedione; VILD, vildagliptin.
Liraglutide recipients also lost significantly more weight than glimepiride-treated patients ($P < 0.001$). As in the prospective studies, rates of hypoglycemia were lower with liraglutide than glimepiride.$^{31}$ The incidence of gastrointestinal AEs was higher in the liraglutide group compared with the glimepiride group ($P < 0.001$).$^{31}$

**GLP-1RAs versus thiazolidinediones**

Five prospective studies compared GLP-1RAs with thiazolidinediones.$^{5,33–35}$

**Prospective studies**

Exenatide BID produced similar reductions in HbA1c to rosiglitazone and pioglitazone in both studies, exenatide BID recipients had weight loss of ~3 kg, whereas those receiving thiazolidinediones had no change in weight.$^{34,35}$ Similar reductions in FG were seen between exenatide BID and rosiglitazone and pioglitazone. Patients receiving exenatide BID had significantly greater weight loss than those receiving thiazolidinediones ($P < 0.0001$); in both studies, exenatide BID recipients had weight loss of ~3 kg, while patients receiving rosiglitazone gained weight and patients receiving pioglitazone had no change in weight.
Studies of exenatide QW showed that reductions from baseline in HbA1c, FG, and weight were either greater or similar than with thiazolidinedione comparators (Table 1).35 In the DURATION-2 study, exenatide QW recipients had significantly greater reductions in HbA1c versus pioglitazone, while in DURATION-4, reductions in HbA1c with exenatide QW and pioglitazone were similar; reductions in FG with exenatide QW and pioglitazone were similar. Significant reductions in weight were seen with exenatide QW in DURATION-2 and -4, whereas patients receiving pioglitazone gained weight (as expected in the presence of a sulfonylurea) in both studies (P < 0.0001 between groups).

The Liraglutide Effect and Action in Diabetes (LEAD)-1 SU study showed that liraglutide (0.6, 1.2, and 1.8 mg/day) was generally more effective as a second-line therapy in improving glycemic parameters and weight than rosiglitazone (Table 1).33 Liraglutide 1.2 mg and 1.8 mg was associated with significantly greater reductions in HbA1c (P < 0.0001) and FG (P < 0.001) than rosiglitazone. Recipients of liraglutide 0.6 mg or 1.2 mg and rosiglitazone gained weight, whereas recipients of liraglutide 1.8 mg lost weight (Table 1); however, the weight gain with the lower dosages of liraglutide was significantly less than that with rosiglitazone, so the differences from baseline in weight were significant between rosiglitazone and all doses investigated (P < 0.0001).

Overall, the rate of hypoglycemia seen with GLP-1RAs was slightly greater than or similar to that seen with thiazolidinediones.8,33–35 The incidence of gastrointestinal AEs led to treatment withdrawal in a higher number of patients in the exenatide group compared with thiazolidinediones in one study.35

**GLP-1RAs versus insulin products**

Twenty-three prospective studies35–57 and seven retrospective studies15,58–63 compared GLP-1RAs with insulin products.

**Prospective studies**

Four trials compared GLP-1RAs and insulin aspart (Table 3).39,47,54,55 Exenatide studies showed that exenatide BID produced a similar or lesser reduction in HbA1c and FG than insulin aspart.38,47,55 In contrast, exenatide BID recipients lost weight, while those using insulin aspart gained weight. In two of the three exenatide studies, the between-group difference in weight was significant (P < 0.001).

In the BEGIN™: VICTOZA® ADD-ON study, liraglutide significantly reduced HbA1c and weight versus insulin aspart, while reductions in FG were similar between treatments (Table 3).54 When liraglutide 1.8 mg was compared with insulin degludec, the reductions in HbA1c and FG were similar between groups; patients receiving liraglutide lost weight while patients receiving insulin gained weight.50

After 26 weeks of treatment, exenatide QW recipients had a significantly greater reduction from baseline in HbA1c than insulin detemir recipients and similar reductions in FG. Similar to liraglutide, those receiving exenatide lost weight, while insulin detemir recipients gained weight (between-group difference, P < 0.0001; Table 3).41

Twelve studies compared GLP-1RAs with insulin glargine (Table 3).36,37,39,40,42,44–46,48,51,52,57 In the exenatide (BID and QW) studies, reductions from baseline in HbA1c were greater or similar to those with insulin glargine, whereas reductions in FG were similar or smaller (Table 3). Furthermore, a significant difference was generally observed between the weight loss with exenatide and the weight gain with insulin glargine (Table 3).

In the AWARD-4 study, compared with insulin glargine, treatment with dulaglutide for 26 weeks resulted in significantly greater reductions in HbA1c in patients also receiving insulin lispro and significantly smaller reductions in FG.39 Patients receiving dulaglutide 1.5 mg lost weight versus baseline, while recipients of dulaglutide 0.75 mg and insulin glargine gained weight; however, the differences between the dulaglutide and insulin glargine groups were significant, irrespective of dulaglutide dose (Table 3).

The comparisons between liraglutide and insulin glargine in the Efficacy Assessment of Insulin Glargine Versus Liraglutide After Oral Agents Failure (EAGLE) and LEAD-5 studies were inconsistent with regard to HbA1c and FG; in the EAGLE study, liraglutide resulted in a lesser reduction in HbA1c and FG than insulin glargine, whereas in the LEAD-5 study, the reduction in HbA1c was greater with liraglutide versus insulin glargine and the reduction in FG was similar between groups.40,57 The change in weight was consistent between the two studies, with liraglutide recipients losing weight and insulin glargine recipients gaining weight (Table 3).

Two studies compared exenatide BID with insulin lispro (Table 3).35,43 In both studies, exenatide BID and insulin lispro reduced HbA1c from baseline to a similar degree. Reductions from baseline in FG were greater or similar with exenatide BID versus insulin lispro; exenatide BID treatment consistently resulted in weight loss, while insulin lispro recipients consistently gained weight.

Generally, the rate of hypoglycemia was lower with GLP-1RAs versus insulin products,35,38–40,43,46,47 or similar
**Table 3** Study details and efficacy results of prospective (randomized controlled and noninterventional) trials of GLP-1RAs versus insulin products

<table>
<thead>
<tr>
<th>Publications (acronym/ClinicalTrials.gov record)</th>
<th>Study design (study duration)</th>
<th>Treatment (patient number)</th>
<th>Background therapy</th>
<th>Change from baseline at study end, GLP-1RAs versus insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Insulin</strong></td>
<td></td>
<td></td>
<td></td>
<td>HbA1c (%)</td>
</tr>
<tr>
<td>Ostenson et al** (CHOICE; NCT00097877)</td>
<td>MC, OL, PG, R in pts with T2D (24 weeks)</td>
<td>ExBiD 5–10 µg (124) Biphase IAsp 30 QD (124)</td>
<td>MET SU</td>
<td>ExBiD: −1.8 IAsp QD: −2.3†† IAsp BID: −2.8††</td>
</tr>
<tr>
<td>Gallwitz et al** (NCT00099619)</td>
<td>MC, OL, PG, R in pts with T2D (26 weeks)</td>
<td>ExBiD 5–10 µg (182) Biphase IAsp 30 TID (181)</td>
<td>SU</td>
<td>ExBiD: −1.0 IAsp: −0.9 IAsp: −1.7</td>
</tr>
<tr>
<td>Nauck et al** (NCT00082407)</td>
<td>MC, OL, PG, R in pts with T2D (52 weeks)</td>
<td>ExBiD 5–10 µg (253) Biphase IAsp BID (248)</td>
<td>IDeg MET</td>
<td>LiRA: −0.7** LiRA: −0.1</td>
</tr>
<tr>
<td>Mathieu et al** (BEGIN: VICTOZA ADD-ON; NCT01388361)</td>
<td>MC, OL, PG, R in pts with T2D (26 weeks)</td>
<td>LIRA 0.6–1.8 mg/day (88) IAsp Qd (89)*</td>
<td>IDeg</td>
<td>LiRa: −1.3 IDeg: −1.4</td>
</tr>
<tr>
<td><strong>Insulin aspart</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bergerenstal et al** (NCT0097877)</td>
<td>MC, O study in pts with T2D (24 months)</td>
<td>ExBiD 5–10 µg (114) Biphase IAsp 30 QD (127)</td>
<td>OADs</td>
<td>ExBiD: −1.0 IAsp: −1.7</td>
</tr>
<tr>
<td><strong>Insulin degludec</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gough et al** (DUAL-1; NCT01336023)</td>
<td>MC, OL, PG, R in pts with T2D (26 weeks)</td>
<td>IDeg/Lira QD (834) LIRA 0.6–1.8 mg QD (415) IDeg QD (414)</td>
<td>MET ± PIO IDeg/Lira QD (665) Lira 0.6–1.8 mg QD (313) IDeg QD (333)</td>
<td>LiRa: −1.3 IDeg: −1.4</td>
</tr>
<tr>
<td><strong>Insulin detemir</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Davies et al** (NCT01003184)</td>
<td>MC, OL, PG, R in pts with T2D (26 weeks)</td>
<td>ExQW 2 mg (111) IDet QD or BID (105)</td>
<td>MET ± SU IDeg</td>
<td>ExQW: −1.3*** IDeg: −0.9</td>
</tr>
<tr>
<td><strong>Insulin glargine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barnett et al** (NCT0099619)</td>
<td>CO, MC, OL, R in pts with T2D (2 x 16 weeks)</td>
<td>ExBiD 5–10 µg/IG QD (68) IG QD/ExBiD 5–10 µg (70)</td>
<td>MET (55.1%) SU (44.9%)</td>
<td>ExBiD: −1.4 IG: −1.4</td>
</tr>
<tr>
<td>Davies et al** (HEELA)</td>
<td>MC, OL, PG, R in pts with T2D (26 weeks)</td>
<td>ExBiD 5–10 µg (118) IG QD (117)</td>
<td>MET SU T2D</td>
<td>ExBiD: −1.3 IG: −1.3</td>
</tr>
<tr>
<td>Diamant et al** (DURATION-3; NCT00645056)</td>
<td>MC, OL, PG, R in pts with T2D (26 weeks)</td>
<td>ExQW 2 mg (233) IG QD (223)</td>
<td>MET ± SU</td>
<td>ExQW: −1.5* IG: −1.3</td>
</tr>
<tr>
<td>Diamant et al** (DURATION-3 extension; NCT00641056)</td>
<td>OL extension of DURATION-3 in pts with T2D (84 weeks)</td>
<td>ExQW 2 mg (233) IG QD (223)</td>
<td>MET ± SU</td>
<td>ExQW: −1.2* IG: −1.0</td>
</tr>
<tr>
<td>Diamant et al** (DURATION-3 extension; NCT00641056)</td>
<td>OL extension of DURATION-3 in pts with T2D (156 weeks)</td>
<td>ExQW 2 mg (194) IG QD (196)</td>
<td>MET ± SU</td>
<td>ExQW: −1.0* IG: −0.8</td>
</tr>
</tbody>
</table>

(Continued)
between groups. Overall, the incidence of gastrointestinal AEs among GLP-1RA-treated patients was higher than in insulin-treated patients, and sometimes led to treatment withdrawal. Retrospective studies

Seven retrospective studies compared GLP-1RAs and insulin products (Table 2), with similar results to the prospective studies; the reduction in HbA1c was greater with GLP-1RAs than insulin in most studies. Where reported, reductions from baseline in FG were not statistically different between

### Table 3 (Continued)

<table>
<thead>
<tr>
<th>Publications (acronym/ ClinicalTrials.gov record)</th>
<th>Study design (study duration)</th>
<th>Treatment (patient number)</th>
<th>Background therapy</th>
<th>Change from baseline at study end, GLP-1RAs versus insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heine et al (NCT0082381)</td>
<td>MC, OL, PG, R in pts with T2D (26 weeks)</td>
<td>ExBiD 5–10 µg (282)</td>
<td>MET</td>
<td>HbA1c (%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IG QD (267)</td>
<td>SU</td>
<td>FG (mmol/L)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ExQW 2 mg (215)</td>
<td>BG</td>
<td>BW (kg)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IG QD (212)</td>
<td>± TGD</td>
<td></td>
</tr>
<tr>
<td>Inagaki et al (NCT0033532)</td>
<td>Japanese pts with T2D (26 weeks)</td>
<td>DULA 0.75 mg QW (181)</td>
<td>BG</td>
<td>HbA1c (%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IG QD (180)</td>
<td>± SU</td>
<td>FG (mmol/L)</td>
</tr>
<tr>
<td>Araki et al (NCT01584232)</td>
<td>MC, OL, PG, R in Japanese pts with T2D (26 weeks)</td>
<td>DULA 0.75 mg QW (293)</td>
<td>ILis</td>
<td>BW (kg)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IG QD (296)</td>
<td>MET</td>
<td></td>
</tr>
<tr>
<td>Blonde et al (AWARD-4; NCT0119126)</td>
<td>MC, OL, PG, R in pts with T2D (52 weeks)</td>
<td>DULA 1.5 mg QW (295)</td>
<td>ILis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>IG QD (296)</td>
<td>MET</td>
<td></td>
</tr>
<tr>
<td>D’Alessio et al (EAGLE)</td>
<td>MC, OL, PG, R in pts with T2D (24 weeks)</td>
<td>LIRA 0.6–1.8 mg QD (489)</td>
<td>MET</td>
<td>HbA1c (%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IG QD (489)</td>
<td>± SU</td>
<td>FG (mmol/L)</td>
</tr>
<tr>
<td>Giorgino et al (AWARD-2; NCT01075282)</td>
<td>MC, OL, PG, R in pts with T2D (7 weeks)</td>
<td>DULA 0.75 mg QW (272)</td>
<td>MET</td>
<td>BW (kg)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IG QD (273)</td>
<td>GLIM</td>
<td></td>
</tr>
<tr>
<td>Russell-Jones et al (LEAD-5; NCT00331851)</td>
<td>MC, OL, PG, R in pts with T2D (26 weeks)</td>
<td>LIRA 1.8 mg QD (230)</td>
<td>MET</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>IG QD (232)</td>
<td>GLIM</td>
<td></td>
</tr>
<tr>
<td>Diamant et al (NCT00966661)</td>
<td>MC, OL, PG, R in pts with T2D (30 weeks)</td>
<td>ExBiD 5–10 µg (315)</td>
<td>MET</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>IG TID (312)</td>
<td>SU</td>
<td></td>
</tr>
<tr>
<td>Xu et al (CONFIDENCE; NCT01147627)</td>
<td>MC, OL, PG, R in treatment-naïve pts with newly diagnosed T2D (48 weeks)</td>
<td>ExBiD 5–10 µg (142)</td>
<td>ExBiD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>IG TID (142)</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** Treatment arms were also compared with a nonrandomized group of patients who received iDeg alone (n = 236); primary end point was change from baseline in HbA1c at 26 weeks; primary end point was change from baseline in HbA1c at 52 weeks; significant difference applies to IG QD versus DULA 0.75 mg QW comparison only. P < 0.05; *P < 0.01; **P < 0.001. GLP-1RA versus INS comparator; P < 0.05; †P < 0.01, INS comparator versus GLP-1RA.

**Abbreviations:** AWARD, Assessment of Weekly Administration of Dulaglutide in Diabetes; βG, biguanide; BID, twice daily; BW, body weight; CHOICE, Changes to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating Injectable Therapy; CO, crossover; CONFIDENCE, Comparison of Glycemic Control and β-Cell Function Amongst Newly Diagnosed Patients With Type 2 Diabetes Treated With Exenatide, Insulin or Pioglitazone: A Multicentre Randomized Parallel-Group Study; DUAL, Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes; DULA, dulaglutide; DURATION, Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention With Exenatide Once Weekly; EAGLE, Efficacy Assessment of Insulin Glargine versus Liraglutide After Oral Agent Failure; ExBiD, exenatide twice daily; ExQW, exenatide once weekly; FG, fasting glucose; GLIM, glimepiride; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; HEELA, Helping Evaluate Exenatide in Patients With Diabetes Compared With Long-Acting Insulin; IPA, insulin aspart; iDeg, insulin degludec; IQs, insulin detemir; IG, insulin glargine; ILis, insulin lispro; INS, insulin; LEAD, Liraglutide Effect and Action in Diabetes; LIRA, liraglutide; MC, multicenter; MET, metformin; NR, not reported; O, observational; OAD, oral antidiabetes drug; OL, open label; PBO, placebo; PG, parallel group; PIO, pioglitazone; pts, patients; QD, once daily; QW, once weekly; R, randomized; SU, sulfonylurea; T2D, type 2 diabetes; TID, three times daily; TGD, thiazolidinedione.
groups. In studies in which the change in weight was reported, GLP-1RA treatment resulted in weight loss, while insulin treatment resulted in weight gain.

Where reported, the incidence of hypoglycemia was either similar between GLP-1RA and insulin treatment groups or lower in those receiving GLP-1RAs. Treatment-related nausea was reported in 10 patients in the exenatide group in one study and did not lead to treatment discontinuation.

**Effect of GLP-1RAs versus other glucose-lowering therapies on cardiovascular risk factors**

The comparative studies identified by the literature search reported only limited information on cardiovascular risk factors and did not assess cardiovascular outcomes.

**GLP-1RAs versus DPP-4is**

Of the 10 prospective trials of GLP-1RAs and DPP-4is, all reported effects on blood pressure (BP) and/or lipid cardiovascular risk factors. Two retrospective studies comparing GLP-1RAs with DPP-4is also reported changes in cardiovascular risk factors. Changes in both diastolic BP and systolic BP (SBP) were variable for GLP-1RAs and DPP-4is, and changes in lipids were generally not significantly different between treatment groups. However, in AW ARD-5, dulaglutide 1.5 mg resulted in a significantly greater reduction in low-density lipoprotein cholesterol compared with sitagliptin.

**GLP-1RAs versus metformin**

Two studies reported data on cardiovascular risk factors after treatment with GLP-1RAs compared with metformin, neither of which showed any clinically significant between-group differences in cardiovascular risk factors.

**GLP-1RAs versus sulfonylureas**

Seven of the nine studies comparing GLP-1RAs with sulfonylureas reported data on cardiovascular risk factors along with one retrospective study. In general, results indicated that the GLP-1RAs were associated with greater reductions in SBP than the sulfonylureas, with numerical reductions in various lipids observed in several studies comparing GLP-1RAs with sulfonylureas.

**GLP-1RAs versus thiazolidinediones**

All five prospective studies comparing GLP-1RAs with thiazolidinediones reported reductions from baseline in BP or fasting lipids. Exenatide significantly reduced measures of cholesterol versus thiazolidinediones in three of these studies.

**GLP-1RAs versus insulin**

Two of four trials comparing GLP-1RAs and insulin aspart reported changes in cardiovascular risk factors. One trial reported a significantly smaller increase in high-density lipoprotein cholesterol with exenatide BID versus insulin aspart.

Eight of ten prospective studies and two extension studies comparing GLP-1RAs with insulin glargine reported changes in cardiovascular risk factors. Overall, numerical reductions in SBP were observed in most of these studies, with greater reductions generally seen with GLP-1RAs than for insulin glargine; significant differences between treatments for fasting lipids also generally favored GLP-1RAs.

Exenatide BID was compared with insulin lispro in two studies. No significant differences between treatment groups were reported for changes in BP or lipids.

Of the seven retrospective studies comparing GLP-1RAs and insulin products, four reported data on cardiovascular risk factors. Numerical reductions in BP and lipid measures were observed across exenatide and insulin therapies.

**Discussion**

GLP-1RAs represent an effective therapeutic option for patients with T2D. Currently, multiple studies provide data on the efficacy of approved GLP-1RAs in T2D (Figure 2). Although their glycemic efficacy is well established versus multiple classes of agents, including insulin, albeit with a notable lack of comparative studies versus sodium-glucose cotransporter 2 inhibitors, GLP-1RAs have additional benefits of modest weight loss and a favorable tolerability profile (Figure 3). These beneficial effects of GLP-1RAs should be considered in context with the increased frequency of nausea with GLP-1RAs, which may limit adherence, and the need for self-injection on a once- or twice-daily or weekly basis.

The efficacy of GLP-1RAs is generally greater than DPP-4is, owing to the supraphysiological concentrations of GLP-1 after administration of the former. This effect on incretin also accounts for the greater weight loss experienced by patients who receive GLP-1RAs versus the neutral weight effects produced by DPP-4is. Glycemic control was also mostly...
similar to that with insulin, largely driven by improvements in postprandial glucose with the short-acting GLP-1RAs, with similar effects on FG as insulin. However, real-world evidence suggests similar glycemic reductions between GLP-1RAs and insulin and within the GLP-1RA class. A real-world study in patients with T2D reported that addition of exenatide BID to basal insulin was as effective as addition of mealtime insulin in reducing HbA1c levels in these patients, with significant...
Figure 3 Comparison of efficacy of GLP-1RAs with other glucose-lowering treatments in type 2 diabetes. General trends in glycemic parameters and body weight (BW) in comparative trials of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and other glucose-lowering therapies. The total number of studies includes studies that reported these parameters.

Abbreviations: DPP-4i, dipeptidyl peptidase-4 inhibitor; FG, fasting glucose; HbA1c, glycated hemoglobin; SU, sulfonylurea; TZD, thiazolidinedione.

reductions in weight ($P<0.01$) and hypoglycemia ($P<0.03$) compared with mealtime insulin.$^{67}$

Data comparing the effects of GLP-1RAs and other classes of glucose-lowering therapy on cardiovascular risk factors were limited but showed favorable effects on BP and lipid levels. Increases in heart rate have been observed with GLP-1RAs in clinical trials, although the underlying mechanisms and clinical relevance of these increases have yet to be established.$^{68}$ The size and duration of increases in mean 24-hour heart rate vary between GLP-1RAs, ranging from transient (1–12 hours) increases of 1–3 beats per minute (bpm) with the short-acting GLP-1RAs exenatide BID and lixisenatide to more prolonged increases during treatment with longer-acting GLP-1RAs (3–4 bpm with exenatide QW or dulaglutide and 6–10 bpm with liraglutide or albiglutide).$^{68}$ Data from cardiovascular outcome trials indicate that the observed increases in heart rate were not associated with an adverse effect on cardiovascular outcomes in patients with T2D.$^{65,68,69}$

Limited clinical data are available regarding the effects of the various GLP-1RAs on cardiovascular outcomes, and none of these studies compared a GLP-1RA with another class of glucose-lowering therapy. The first published study with prospective outcomes data was the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial,$^{70}$ which found no significant difference in rates of cardiovascular events with lixisenatide versus placebo.$^{6}$ A similar study investigating the effects of liraglutide on cardiovascular outcomes versus placebo.$^{1}$ Finally, the Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6), which evaluated the effect of semaglutide (added on to standard care) on cardiovascular outcomes, demonstrated the noninferiority of semaglutide to placebo, with a significant reduction in cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction in the semaglutide group.$^{69}$

Results of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial, evaluating the effect of exenatide QW on major adverse cardiovascular events (MACE) when given in addition to usual care;$^{71}$ the Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) study, evaluating the effects of dulaglutide on MACE;$^{72}$ and the HARMONY Outcomes study, evaluating the effects of albiglutide on MACE,$^{73}$ are all awaited and are expected to help contribute to the existing evidence regarding the impact of the GLP-1RAs on cardiovascular outcomes.

With the limited availability of prospective data, we can glean some information from meta-analyses and pooled analyses that have been conducted in an attempt to elucidate the effects of GLP-1RAs on cardiovascular outcomes. For example, a prespecified meta-analysis, which evaluated cardiovascular risk in the dulaglutide clinical development program,$^{74}$ indicated that there were no significant differences between dulaglutide and placebo groups with regard to the risk of MACE. Similarly, a meta-analysis of cardiovascular events occurring during treatment with albiglutide, placebo,
or active comparators in the HARMONY clinical trial program determined there was no significant difference between albiglutide and comparator for the risk of MACE or hospital admission for unstable angina.

The effect of exenatide BID on cardiovascular outcomes has also been assessed in a pooled meta-analysis of cardiovascular safety data from 12 long-term, randomized, placebo- or insulin comparator-controlled trials. The pooled relative risk for primary MACE for users of exenatide BID versus the comparator favored exenatide, suggesting no increased cardiovascular risk associated with exenatide use versus insulin or placebo. Two additional meta-analyses did not find any increase in the incidence of MACE in users of GLP-1RAs compared with comparators. Both studies showed that the GLP-1RAs were associated with a significantly lower risk of MACE compared with placebo, but not with active comparators (with the exception of pioglitazone). Consistent with these two studies, a sequential analysis of long-term trials comparing the effect of GLP-1RAs with other glucose-lowering drugs or placebo as well as a large comparative safety study of GLP-1RAs versus other glucose-lowering agents both demonstrated no significant difference in the risk of cardiovascular events between drug classes.

Real-world data can also provide some insight into the impact of the GLP-1RAs on cardiovascular risk in patients with T2D. Retrospective studies have suggested that exenatide BID, with or without concomitant insulin, significantly reduced the risk of cardiovascular events compared with insulin and that exenatide BID is associated with a lower risk of cardiovascular events and hospitalizations versus other glucose-lowering therapies.

The present review included prospective and retrospective studies that compared the efficacy and safety of approved GLP-1RAs with currently available glucose-lowering therapies in the treatment of patients with T2D, with data showing clinical benefit of GLP-1RAs over other glucose-lowering therapies. However, it is critical to consider the patient selection criteria, background medications, properties of the individual GLP-1RAs, drug exposure across dose intervals, and outcome definitions of each study. Furthermore, the patient characteristics in these studies need to be taken into account to assess the generalizability of the results to the T2D population at large; overly strict criteria limit the applicability of the data to everyday clinical practice.

**Conclusion**

This systematic analysis shows that GLP-1RAs were generally as effective as, or more effective than, oral glucose-lowering therapies in improving glycemic parameters such as HbA1c and FG in patients with T2D. The reduction in HbA1c with GLP-1RAs tended to be similar or smaller compared with the reductions achieved with insulin therapy, with less hypoglycemia. GLP-1RAs were consistently more effective at reducing weight than oral glucose-lowering therapies and insulin. Additionally, the GLP-1RAs appeared to have favorable effects on cardiovascular risk factors such as BP and lipid levels. In summary, GLP-1RAs are an effective, safe, and well-tolerated treatment option for T2D, with minimal risk of hypoglycemia and providing modest weight loss.

**Acknowledgments**

Sheridan Henness, PhD, of inScience Communications, Springer Healthcare, provided medical writing support funded by AstraZeneca. The development of this manuscript was supported by AstraZeneca.

**Author contributions**

All authors have contributed sufficiently to the project to be included as authors. The authors contributed equally to the conception and design of the systematic review and literature search, interpretation of the results, and drafting of the manuscript.

**Disclosure**

PA Levin has received grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi. He is a consultant for AstraZeneca, Novo Nordisk, and Sanofi, and a speaker for AstraZeneca, Boehringer Ingelheim, Eli Lily, GlaxoSmithKline, Janssen, Novo Nordisk, and Sanofi. H Nguyen was an employee of AstraZeneca at the time this review was conceived and drafted. ET Wittbrodt is an employee of AstraZeneca. SC Kim has received research grants to the Brigham and Women’s Hospital from AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly, and Pfizer. The authors report no other conflicts of interest in this work.

**References**


